Taken together, this indicates that MCL-1 inhibition can sensitize different breast cancer subtypes to a range of therapies, though it is likely that refined treatment strategies will be required to circumvent significant toxicity in normal tissues. The gene discussed is MCL1; the disease is breast carcinoma.